Carbapenem-sparing antibiotic regimens for infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae in intensive care unit

Clinical Infectious Diseases

Volumn 56, Issue 5, 2013, Pages 697-700

  Sbrana, Francesco ^a   Malacarne, Paolo ^a   Viaggi, Bruno ^a   Costanzo, Sergio ^b   Leonetti, Piero ^b   Leonildi, Alessandro ^a   Casini, Beatrice ^b   Tascini, Carlo ^a   Menichetti, Francesco ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

intensive care unit; KPC producing Klebsiella pneumoniae; outcome

Indexed keywords

CARBAPENEMASE; COLISTIMETHATE; FOSFOMYCIN; GENTAMICIN; TIGECYCLINE;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BLOODSTREAM INFECTION; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; EPSILOMETER TEST; FEMALE; GRAM NEGATIVE SEPSIS; HOSPITAL PATIENT; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MALE; MORTALITY; MULTIPLE TRAUMA; NEPHROTOXICITY; PRIORITY JOURNAL; SEPSIS; TREATMENT RESPONSE; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 84873697678     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis969     Document Type: Article

References (12)

1. Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 2011; 53:60-7.
2. Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother 2010; 65:1119-25.
3. Zarkotou O, Pournaras S, Tselioti P, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect 2011; 17:1798-803.
4. Qureshi ZA, Paterson DL, Potoski BA, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 2012; 56:2108-13.
5. Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by KPC-producing Klebsiella pneumoniae: importance of combination therapy. Clin Infect Dis 2012; 55:943-50.
6. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008; 29:1099-106.
7. Horan TC, Andrus M, Dudeck M. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008; 36:309-32.
8. Levy MM, Fink MP, Marshall JC, et al. International Sepsis Definitions Conference. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definition Conference. Int Care Med 2003; 29:530-8.
9. Cunha BA. Pharmacokinetic considerations regarding tigecycline for multidrug-resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii urosepsis. J Clin Microbiol 2009; 47:613.
10. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Clinical breakpoints. Available at: http://www.eucast.org/clinical-breakpoints/. Accessed 1 January 2012.
11. Le J, McKee B, Srisupha-Olarn W, Burgess DS. In vitro activity of carbapenems alone and in combination with amikacin against KPCproducing Klebsiella pneumoniae. J Clin Med Res 2011; 3:106-10.
12. Dalfino L, Puntillo F, Mosca A, et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis 2012; 54:1720-6.